For the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients.
Pre Noc Submission:
Hoffmann-La Roche Limited
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Hoffmann-La Roche Limited has requested a voluntary withdrawal of the pCODR 10157 Entrectinib (TBD) for NTRK+ solid tumours submission.
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.